Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 5/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 5/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | STS | P08842 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20060897 | 0.82 | GPR119 (0.51) | NR1H2NR1H3GPR119 | |
| SCHEMBL20077730 | 0.81 | GPR119 (0.56) | NR1H2NR1H3GPR119 | |
| SCHEMBL3486236 | 0.77 | NR1H2 (0.66) | NR1H2NR1H3GPR119 | |
| SCHEMBL20077130 | 0.77 | NR1H2 (0.54) | NR1H2NR1H3MEN1KMT2AMAPT | |
| SCHEMBL22895030 | 0.77 | NR1H2 (0.54) | NR1H2NR1H3MEN1KMT2AMAPT | |
| SCHEMBL30031581 | 0.76 | NR1H2 (0.51) | NR1H2NR1H3GPR119MEN1KMT2A | |
| SCHEMBL20077132 | 0.75 | NR1H2 (0.46) | NR1H2NR1H3GPR119MEN1KMT2A | |
| SCHEMBL30032228 | 0.75 | ALDH1A1 (0.60) | NR1H2NR1H3GPR119MEN1KMT2A | |
| SCHEMBL22284361 | 0.75 | GPR119 (0.53) | NR1H2NR1H3GPR119 | |
| SCHEMBL22284362 | 0.75 | GPR119 (0.53) | NR1H2NR1H3GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10894775-B2 | Piperidine derivatives as liver X receptor beta agonists, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2021-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10894775-B2 | Piperidine derivatives as liver X receptor beta agonists, compositions, and their use | NR1H2, NR1H3, ADRB1 | NR1H2 1/4885NR1H3 2/4885GPR119 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.